BUZZ-Sangamo jumps as US FDA fast-tracks drug for chronic nerve pain
Reuters
Yesterday
BUZZ-Sangamo jumps as US FDA fast-tracks drug for chronic nerve pain
** Shares of drug developer Sangamo TherapeuticsSGMO.O rise 6% to $0.47
** Co says U.S. FDA granted fast-track designation to its experimental treatment, ST-503, for a severe form of chronic nerve pain
** ST-503 is experimental epigenetic regulator aimed at providing non-opioid treatment options, co says
** U.S. FDA's "fast track" tag aims to speed development and review of drugs for serious conditions with unmet medical needs
** Co expects to dose first patient in its early-stage trial in coming months - SGMO
** Including session's move, stock down ~56% YTD
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.